Skip Nav Destination

On Location

Updates from major medical meetings in the field of hematology/oncology

Daratumumab Plus Lenalidomide Shows MRD, PFS Benefit in Newly Diagnosed MM After AHCT in Clinically Relevant Subgroups

Katie Robinson

Patients in R/R Marginal Zone Lymphoma Cohort of ELM-2 Show Superior Outcomes With Odronextamab

Lara C. Pullen, PhD

Bispecific T-Cell Engager Results in CR, Clears MRD in Patients with R/R Follicular Lymphoma

Anna Azvolinsky, PhD

Initial Results Confirm Safety of Lower-Dose Teclistamab as Maintenance in NDMM

Khylia Marshall

Teclistamab-Based Induction Regimens Achieve MRD Negativity in Patients With Transplant-Eligible NDMM

Katie Robinson

Daratumumab Shows Better Outcomes Than Active Monitoring for Smoldering Multiple Myeloma

Lara C. Pullen, PhD

Quadruple Combination with Brentuximab Vedotin, Nivolumab Continues to Show Strong Efficacy in Early-Stage cHL

Anna Azvolinsky, PhD

High Incidence of Postpartum Hemorrhage in Hemophilia Carriers

Ruth Jessen Hickman, MD

Pomalidomide Found Safe, Highly Effective for Epistaxis in HHT

Ruth Jessen Hickman, MD

Geriatric Assessment-Guided Conditioning Reduced Non-Relapse Mortality for Transplant in Myeloid Malignancies

Leah Lawrence

Study Validates SCD Biomarker for Targeted P-Selectin Therapy Response

Katie Robinson

CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds

Thomas R. Collins

Ibrutinib-Rituximab Outperforms Chemotherapy in Front-Line MCL, Trial Finds

Thomas R. Collins

Revised Cytoreductive Start Criteria in PV Identify Thrombotic Risk Regardless of Conventional Risk Category

Katie Robinson

Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL

Anna Azvolinsky, PhD

AI Algorithm Using ECG, D-Dimer Provides Impressive Accuracy for PE Diagnosis

Ruth Jessen Hickman, MD

MRD-Guided Therapy Improves Quality of Life for Patients With CLL

Anna Azvolinsky, PhD

Eliminating Modifiable Risk Factors Lowers Bleeding Risk in Patients With Cancer, VTE, Study Finds

Thomas R. Collins

Findings Indicate TP53 Alterations Play a Significant Role in Myeloproliferative Neoplasm Disease Progression

Khylia Marshall

Considerable Morbidity and Mortality Seen in AIHA, Long-Term Study Finds

Thomas R. Collins

1 2 3 4 5

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
December 2024

Advertisement intended for health care professionals

On Location

ASH Publications

American Society of Hematology

On Location

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only